Abstract 230 - IMPIEGO DEI GLICOPEPTIDI NELLA ... - SIMIT

More documents

Recommendations

Info

NNRTI based che continuano NNRTI based che interrompono 36 40.8 (8.6) 12 37.1 (8.6) Totale NNRTI 48 39.9 (8.8) 6% 273.7 (135.3) 8.3% 25% 232.2 (121.1) 17% 10.4% 263.12(138.4) 11% 102 10° CONGRESSO NAZIONALE SIMIT
103 10° CONGRESSO NAZIONALE SIMIT Abstract 251 - MONOTHERAPY WITH ATAZANAVIR AS A SIMPLIFICATION STRATEGY: RESULTS FROM AN OBSERVATIONAL STUDY. - Cossarini F.* [1] , Salpietro S. [1] , Galli L. [1] , Gianotti N. [1] , Nozza S. [1] , Soagnuolo V. [1] , Hasson H. [1] , Bossolasco S. [1] , Pizzocolo C. [1] , Lazzarin A. [1] , Tambussi G. [1] , Castagna A. [1] - [1] San Raffaele Scientific Institute ~ Milano INFEZIONI DA HIV Premessa: Protease Inhibitors (PI) monotherapy is an appealing treatment simplification strategy for many HIV-infected patients. Atazanavir has not been studied as extensively as other PIs for monotherpy treatment. Obiettivo: Aim of the study was to describe the immunovirological response to atazanavir monotherapy (ATV/r 300/100 mg or ATV 400 mg). We studied HIV-infected individuals followed at our Clinic who switched from a HAART regimen to either a ATV/r or an ATV monotherapy while virologically suppressed (HIV-RNA50 copies/mL; and the immunological variation defined as CD4+ and CD8+ change from the start of atazanavir monotherapy. Results are expressed as median (IQR) or n(%). Risultati: 43 subjects were included: ATV/r or ATV were prescribed in 30(68%) and 13(30%) patients, respectively. Patients switched to monotherapy due to toxicity [23(53%)] or treatment simplification [18 (47%)]. Twenty-four (56%) patients were on a PI regimen [17 (40%) on atazanavir] before monotherapy. After a median of 10.0 (5.4-23.4) months of follow-up, 3(7%) subjects experienced virological failure. CD4+ change was -9(- 79/+75)cells/mcl; CD4% change was 1.7(-2.7/+4.4), CD8+ change was -157(- 360/+cells/mcl and CD8% change was -6(-7.4/-1). Additional patients characteristics and results are in Table-1. Conclusione: We observed a very low proportion of virological failure on atazanavir monotherpy, with stable CD4+ counts and a reduction in CD8+ counts. Although the small sample size and the retrospective nature of this study, our results may support a potential role for atazanavir in PI monotherapy simplification strategies and encourage further studies on this topic.
Page 1 and 2:
Abstract 230 - IMPIEGO DEI GLICOPEP
Page 3 and 4:
Abstract 223 - VANCOMICINA IN INFUS
Page 5 and 6:
5 10° CONGRESSO NAZIONALE SIMIT Ab
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
11 10° CONGRESSO NAZIONALE SIMIT A
Page 13 and 14:
Azithromycin R 2 Gentamicin S 1 Van
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Abstract 9 - SIEROPREVALENZA DELL
Page 29 and 30:
Page 31 and 32:
Abstract 170 - MALATTIA DI LYME A B
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Abstract 144 - EPIDEMIA DI TRICHINE
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52: 51 10° CONGRESSO NAZIONALE SIMIT A
Page 57 and 58: 16 Legati al paziente 4 Non identif
Page 61 and 62: Nausea 24 % Rinorrea 21 % Congiunti
Page 75 and 76: 75 10° CONGRESSO NAZIONALE SIMIT F
Page 81 and 82: Via di trasmissione TD vs altre 65.
Page 83 and 84: Abstract 194 - LESIONE EPIGLOTTICA
Page 101: 101 10° CONGRESSO NAZIONALE SIMIT
Page 105 and 106: 105 10° CONGRESSO NAZIONALE SIMIT
Page 109 and 110: Genere maschile, n 30 (58%) Età me
Page 137 and 138: TAS>51 TAS95%, n (%) 19 (61,3) 13 (
Page 153 and 154:
153 10° CONGRESSO NAZIONALE SIMIT
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Abstract 262 - SINDROME DI LYELL IN
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Abstract 117 - POTENZIALITÀ RIPROD
Page 173 and 174:
Abstract 137 - INFEZIONI DA HBV, HC
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Demografiche Comorbidità Sintomi d
Page 193 and 194:
Neisseria Meningitidis S. Pneumonia
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229 and 230:
Page 231 and 232:
Page 233 and 234:
Page 235 and 236:
Page 237 and 238:
Page 239 and 240:
Abstract 55 - EPATITE VIRALE ACUTA
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
Page 247 and 248:
Page 249 and 250:
Page 251 and 252:
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
IL28b: CC HCVRNA UI/L, mediana (IQR
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
Abstract 23 - UN CASO INUSUALE DI I
Page 265 and 266:
Page 267 and 268:
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
KIR2DL1 - HLA-C2 car 31/41 (75.6%)
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
Abstract 305 - STREPTOCOCCAL SHOCK
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
Study ID Greif (2000) Pryor (2004)
Page 309 and 310:
Page 311 and 312:
Page 313 and 314:
Page 315 and 316:
Page 317 and 318:
Page 319 and 320:
Page 321 and 322:
Page 323 and 324:
Page 325 and 326:
Page 327 and 328:
Abstract 89 327 10° CONGRESSO NAZI
Page 329 and 330:
Page 331 and 332:
Abstract 72 - GRAVE QUADRO DI IRIS
Page 333 and 334:
show all

Abstract 230 - IMPIEGO DEI GLICOPEPTIDI NELLA ... - SIMIT

Create successful ePaper yourself

Delete template?

Save as template?